Literature DB >> 26763834

Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study.

Wenjing Sun1, Hongli Cui1, Ning Li1, Yanling Wei1, Shujie Lai1, Yang Yang1, Xinru Yin1, Dong-Feng Chen1.   

Abstract

AIM: Non-alcoholic fatty liver disease (NAFLD)-related advanced hepatic fibrosis is associated with liver and cardiovascular morbidity and mortality. This study aims to compare the FIB-4 index, NAFLD fibrosis score (NFS) and BARD score for prediction of advanced liver fibrosis.
METHODS: Pooled sensitivity, specificity, diagnostic odds ratio (DOR), summary receiver-operator curves (SROC) and Spearman's rank correlation coefficient were used to examine the accuracy of each non-invasive scoring system for predicting NAFLD-related advanced fibrosis.
RESULTS: Four studies with 1038 adult patients were included in this meta-analysis. A total of 135 patients (13.0%) had advanced fibrosis. In the FIB-4 index group, pooled sensitivity and specificity with 95% confidence interval (CI), and the area under the ROC (AUROC) were 0.844 (0.772-0.901), 0.685 (0.654-0.716) and 0.8496 ± 0.0680, respectively, at a cut-off of 1.30. At a threshold of 3.25, the same parameters were 0.38 (0.30-0.47), 0.96 (0.95-0.98) and 0.8445 ± 0.0981. At a cut-off of -1.455, values were 0.77 (0.69-0.84), 0.70 (0.67-0.73) and 0.8355 ± 0.0667, respectively. At a 0.676 cut-off, pooled sensitivity and specificity with 95% CI were 0.27 (0.19-0.35) and 0.98 (0.96-0.98), respectively; and the AUROC was 0.647 ± 0.2208. In the BARD score group, pooled sensitivity and specificity with 95% CI were 0.74 (0.66-0.81) and 0.66 (0.63-0.69), respectively; and the AUROC was 0.7625 ± 0.0285.
CONCLUSION: FIB-4 index with a 1.30 cut-off has better diagnostic accuracy than the FIB-4 index with a 3.25 cut-off, NFS and BARD score, despite showing its limited value for predicting NAFLD-related advanced fibrosis.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  hepatic fibrosis; meta-analysis; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; non-invasive assessment

Year:  2016        PMID: 26763834     DOI: 10.1111/hepr.12647

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  52 in total

1.  Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.

Authors:  Cyrielle Caussy; Veeral H Ajmera; Puneet Puri; Cynthia Li-Shin Hsu; Shirin Bassirian; Mania Mgdsyan; Seema Singh; Claire Faulkner; Mark A Valasek; Emily Rizo; Lisa Richards; David A Brenner; Claude B Sirlin; Arun J Sanyal; Rohit Loomba
Journal:  Gut       Date:  2018-12-19       Impact factor: 23.059

2.  NAFLD: The clinical and economic burden of NAFLD: time to turn the tide.

Authors:  Manal F Abdelmalek
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-09       Impact factor: 46.802

Review 3.  NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?

Authors:  Shivaram P Singh; Rakesh K Barik
Journal:  J Clin Exp Hepatol       Date:  2019-09-21

4.  A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease.

Authors:  Heather Mary-Kathleen Kosick; Aline Keyrouz; Oyedele Adeyi; Giada Sebastiani; Keyur Patel
Journal:  Dig Dis Sci       Date:  2021-01-03       Impact factor: 3.199

Review 5.  Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Pharmaceut Med       Date:  2019-12

6.  Nonalcoholic Fatty Liver Disease in Children.

Authors:  Katherine F Sweeny; Christine K Lee
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-12

7.  Non-invasive assessment of liver alterations in Senning and Mustard patients.

Authors:  Nicole Nagdyman; Siegrun Mebus; Johanna Kügel; Reinhart Zachoval; Dirk-André Clevert; Siegmund Lorenz Braun; Guido Haverkämper; Bernd Opgen-Rhein; Felix Berger; Sophia Horster; Jörg Schoetzau; Claudia Pujol Salvador; Ulrike Bauer; John Hess; Peter Ewert; Harald Kaemmerer
Journal:  Cardiovasc Diagn Ther       Date:  2019-10

8.  A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis.

Authors:  Tae Gyu Oh; Susy M Kim; Cyrielle Caussy; Ting Fu; Jian Guo; Shirin Bassirian; Seema Singh; Egbert V Madamba; Ricki Bettencourt; Lisa Richards; Ruth T Yu; Annette R Atkins; Tao Huan; David A Brenner; Claude B Sirlin; Michael Downes; Ronald M Evans; Rohit Loomba
Journal:  Cell Metab       Date:  2020-06-30       Impact factor: 27.287

9.  High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes.

Authors:  Haruka Saito; Hayato Tanabe; Akihiro Kudo; Noritaka Machii; Moritake Higa; Satoshi Yamaguchi; Gulinu Maimaituxun; Kazumichi Abe; Atsushi Takahashi; Kenichi Tanaka; Koichi Asahi; Hiroaki Masuzaki; Hiromasa Ohira; Junichiro J Kazama; Michio Shimabukuro
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

Review 10.  Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda.

Authors:  Amit G Singal; Anna S Lok; Ziding Feng; Fasiha Kanwal; Neehar D Parikh
Journal:  Clin Gastroenterol Hepatol       Date:  2020-09-19       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.